Mayzent (Siponimod): An S1P Modulator for Secondary Progressive MS

By Dr. Emily Hanover

Mayzent (Siponimod): An S1P Modulator for Secondary Progressive MS is an in-depth exploration of one of the most advanced treatments available for secondary progressive multiple sclerosis (SPMS). Written by Dr. Emily Hanover, this comprehensive guide delves into the pharmacology, clinical efficacy, and safety profile of Mayzent, offering a clear understanding of how this S1P receptor modulator works to delay disease progression and improve patient outcomes.

This book covers the underlying pathophysiology of multiple sclerosis, the mechanism of action of S1P modulators, and the latest clinical trials evaluating the effectiveness of Mayzent in SPMS. It also discusses key considerations such as genetic testing for CYP2C9 variants, dosing guidelines, and potential side effects, making it an essential resource for healthcare providers, researchers, and patients seeking a deeper understanding of this innovative therapy.

With detailed comparisons to other disease-modifying therapies, insights into future research directions, and practical guidance for monitoring and managing treatment, this book provides a valuable reference for anyone looking to navigate the evolving landscape of multiple sclerosis treatment.

• Format: Paperback
• Language: English
• ISBN: B0F199DHPL
• ISBN13: 9798313827834
• Release Date: March 2025
• Publisher: Independently Published
• Length: 192 Pages
• Weight: 0.58 lbs.
• Dimensions: 0.4" x 6.0" x 9.0"